Imaging immune cells in brain tumors with a special PET scan tracer
Tests a scan tracer that shows immune cells in adults with removable brain tumors.
Key facts
- Who runs it
- Jonsson Comprehensive Cancer Center
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Registry title
- Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 20 people, planned
- Started
- 5 Dec 2024
- Expected to end
- 31 Jan 2028
- Type of study
- Interventional
- Treatments tested
- Advanced Magnetic Resonance Imaging
- Brain Surgery
- Electronic Health Record Review
- Immuno-Positron Emission Tomography Scan
- Magnetic Resonance Imaging
- Stereotactic Biopsy
- Zirconium Zr 89 Crefmirlimab Berdoxam
- Record updated
- 5 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a brain tumor who are already scheduled for standard surgery to remove it. Before surgery, they get a special PET scan that shows immune cells in the tumor.
- Age
- 18 years and older
- Sex
- Male and female
- Disease stage
- A brain tumor that can be removed by surgery. This includes cancer that has spread to the brain, gliomas of any grade, and meningiomas.
- Earlier treatment
- Surgery to remove the tumor must already be planned as part of standard care.
Main reasons for not taking part
- Not cleared by doctors to have surgery
- Cannot tolerate an MRI scan or a PET/CT scan
- Pregnant or breast-feeding women
- Problems with the spleen, or the spleen has been removed
- Any condition that rules out gadolinium contrast dye used in MRI
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Male or female >= 18 years of age
- Documentation of a diagnosis of brain tumor including brain metastases, any grade of gliomas and meningiomas
- The participant is scheduled for standard of care surgical tumor resection
- The participant (or legally acceptable representative if applicable) provides written informed consent for the trial
Who cannot take part
- Not medically cleared for surgery
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
- Serum creatinine OR measured or calculated creatinine clearance (Glomerular filtration rate [GFR] can be use in place of creatinine or creatinine clearance [CrCl]) =< 1.5 X institutional upper limit of normal (ULN) OR >= 60mL/min for subjects with creatinine levels > 1.5 X institutional ULN; Creatinine clearance should be calculated per institutional standard
- Serum total bilirubin: =< 1.5 X institutional ULN OR direct bilirubin =< institutional ULN for subjects with total bilirubin levels > 1.5 institutional ULN
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X institutional ULN OR =< 5 X institutional ULN for subjects with Gilberts syndrome
- Albumin >= 2.5 mg/dL
- Male or female < 18 years of age
- Individuals who cannot tolerate MRI scan or PET/CT scan
- Pregnant or breast-feeding women
- Patients with splenic dysfunction or post splenectomy
- Any abnormalities that would be a contraindication to gadolinium-based contrast agent
This trial is currently available in United States.
- UCLA / Jonsson Comprehensive Cancer CenterLos Angeles, United StatesContact: Sichen LiTaking people
About the trial
What the trial wants to find out
This phase I trial studies how well zirconium (Zr)-89 crefmirlimab berdoxam and immuno-positron emission tomography (PET) identifies areas of immune cell activity in patients with brain tumors that can be removed by surgery (resectable). One important predictor of the immune response is the presence and change in CD8 positive (+) tumor infiltrating lymphocytes (TIL) cells. Identifying the presence and changes in CD8+ cells can be challenging, particularly for participants with central nervous system (CNS) tumors, and usually requires invasive procedures such as repeat tissue biopsies, which may not accurately represent the immune status of the entire tumor. Zr-89 crefmirlimab berdoxam is known as a radioimmunoconjugate which consists of a radiolabeled anti-CD8+ minibody whose uptake can be imaged with PET. Upon administration, Zr 89 crefmirlimab berdoxam specifically targets and binds to the CD8+ cells. This enables PET imaging and may detect CD8+ T-cell distribution and activity and may help determine the patient's response to cancer immunotherapeutic agents more accurately. Giving Zr-89 crefmirlimab berdoxam along with undergoing immuno-PET imaging may work better at identifying immune cell activity in patients with resectable brain tumors.
The group in the trial
- Treatment (Zr-89 crefmirlimab berdoxam + ImmunoPET)Treatment being tested
Patients receive Zr-89 crefmirlimab berdoxam IV over 5-10 minutes 3 days prior to scheduled surgical resection. Approximately 24 hours after receiving Zr-89 crefmirlimab berdoxam, patients undergo immuno-PET scans. Patients then undergo scheduled standard of care surgical resection of the brain tumor and brain biopsy. Additionally, patients undergo advanced physiologic and metabolic MRI and MRI prior to surgery.
Treatment: Advanced Magnetic Resonance Imaging, Brain Surgery, Electronic Health Record Review, Immuno-Positron Emission Tomography Scan, Magnetic Resonance Imaging, Stereotactic Biopsy, and Zirconium Zr 89 Crefmirlimab Berdoxam
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Biologic Validation of Zr-89 Crefmirlimab Berdoxam CD8+ Minibody ImmunoPET in Human Brain Tumors
- Plain-language title
- Imaging immune cells in brain tumors with a special PET scan tracerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 5 February 2026